Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Zofia Piotrowska, MD, MPH
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beth Israel Deaconess
Boston, Massachusetts, United States
Daniel Costa, MDRecruiting - Dana Farber Cancer Institute
Boston, Massachusetts, United States
Michael Cheng, MDRecruiting - Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Henning Willers, MDZofia Piotrowska, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Jun 2019
- Primary completion
- 30 Apr 2022
- Completion
- 30 Apr 2024
- Last update posted
- 16 Dec 2020
- Registered enrollment
- 30
- Registry id
- NCT03891615
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.